Evidence map›Paper›PMID 41604262›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Mapping targetable sites on the human surfaceome for the design of novel binders.

Petra E M Balbi, Ahmed Sadek, Anthony Marchand, Ta-Yi Yu, Jovan Damjanovic, Sandrine Georgeon, Joseph Schmidt, Simone Fulle, Che Yang, Hamed Khakzad and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Petra E M Balbi *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0009-0000-4080-9216
Ahmed Sadek *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0009-0009-0724-7990
Anthony Marchand *Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0000-0003-2864-0408
Ta-Yi YuNovo Nordisk A/S, AI & Digital Innovation, R&D, Seattle, WA 98109.
Jovan DamjanovicNovo Nordisk A/S, AI & Digital Innovation, R&D, Lexington, MA 02421.ORCID 0000-0002-6019-4738
Sandrine GeorgeonInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.
Joseph SchmidtInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.
Simone FulleNovo Nordisk A/S, AI & Digital Innovation, R&D, Måløv 2760, Denmark.
Che YangNovo Nordisk A/S, AI & Digital Innovation, R&D, Måløv 2760, Denmark.ORCID 0000-0002-4591-5373
Hamed KhakzadCentre Inria de l'Université de Lorraine, LORIA, CNRS, Nancy 54000, France.ORCID 0000-0002-8556-0650
Bruno E CorreiaInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0000-0002-7377-8636

Funding

ERC Consolidator replacement 724228French Agence Nationale de la Recherche (ANR) ANR-22-CPJ2-0075-01National Center of Competence in Research in Molecular Systems Engineering 182895NovoSTAR program 538383Swiss NSF 310030_197724
6 · The paper itself

Abstract

The human cell surfaceome, integral to cell communication and disease mechanisms, presents a prime target for therapeutic intervention. De novo protein binder design against these cell surface proteins offers a promising yet underexplored strategy for drug development. However, the vast search space and limited data on natural or competitive binders have historically limited experimental success. In this study, we systematically analyzed the entire human surfaceome, identifying approximately 4,500 targetable sites and introducing potential binding seeds for initiating protein design applications. To validate these seeds, we implemented two experimental approaches (protein scaffolding and peptide cyclization) on three representative targets (FGFR2, IFNAR2, and HER3). Our results revealed a high success rate, showing that seeds provide valuable starting points for binder design against our identified targetable sites, as well as the need for constant improvements of computational protein design pipelines utilizing machine learning and physics-based methods. Additionally, we present SURFACE-Bind, an interactive database offering open access to all generated data. The high-throughput computational design methods and target-specific binder seeds established here pave the way for a new generation of targeted therapeutics for the human surfaceome.

Indexed as

Drug DesignMembrane ProteinsBinding SitesHumansProtein BindingReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanMembrane ProteinsReceptor, Fibroblast Growth Factor, Type 2de novo protein designgeometric deep learninghuman surfaceomemapping of targetable binding sitesprotein–protein and protein-peptide interactions

Identifiers

PMID41604262
PMCPMC12867733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.